Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III Studies

Abstract

Early treatment-related BP increases do not predict clinical benefit from bevacizumab based on PFS or OS outcomes. BP increases do not appear to have general prognostic importance for patients with advanced cancer.